At the recently held Conference on Retroviruses and Opportunistic Infections at the Washington State Convention Center in Seattle, details of clinical trial results presented by CytoDyn Inc. (OTCQB: CYDY) for its monoclonal antibody, PRO 140, were well received. The UK-based charity, NAM Aidsmap, known for its pioneering work in providing information on HIV/AIDS therapies, hailed the poster presentations on monoclonal antibodies such as PRO 140, noting the promise they hold as long-acting therapies for HIV/AIDS patients with limited treatment options due to drug resistance (http://nnw.fm/dFPp2). PRO 140’s efficacy has already offered hope to a number of HIV positive patients in a series of clinical trials. On behalf of CytoDyn, Dr. Kush Dhody of Amarex Clinical Research presented, in a well-attended special themed discussion, the latest results from the extension study of a Phase IIb trial of PRO 140 as a single agent maintenance therapy for people who had achieved viral suppression on standard combination antiretroviral therapy (ART) and wanted to switch to a treatment with fewer side effects to improve their quality of life and provide simpler compliance.
Antibodies are produced by the body as a first line of defense against pathogens such as viruses and bacteria. Each antibody is uniquely developed to combat a particular antigen, which it then counters by flagging the intruder as such, to be destroyed by microphages, or by neutralizing it. Monoclonal antibodies are artificially produced antibodies that have been cloned from…
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer